omeprazole has been researched along with Psoriasis in 4 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with moderate to severe chronic plaque psoriasis (n = 21) received single oral doses of sensitive probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) on day 1, followed by 12 weeks of subcutaneous risankizumab treatment of 150 mg once every 4 weeks from day 8 to day 92, and again the same cocktail of substrates on day 98." | 5.30 | Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. ( Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y, 2019) |
| " The probe cocktail was generally well-tolerated when administered in combination with guselkumab in patients with psoriasis." | 2.94 | Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. ( Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Y | 1 |
| Xu, Y | 1 |
| Zhuang, Y | 1 |
| Piantone, A | 1 |
| Shu, C | 1 |
| Chen, D | 1 |
| Zhou, H | 1 |
| Xu, Z | 1 |
| Sharma, A | 1 |
| Khalilieh, S | 1 |
| Hussain, A | 1 |
| Montgomery, D | 1 |
| Levine, V | 1 |
| Shaw, PM | 1 |
| Bodrug, I | 1 |
| Mekokishvili, L | 1 |
| Bailey-Smith, C | 1 |
| Glasgow, XS | 1 |
| Cheng, A | 1 |
| Martinho, M | 1 |
| Iwamoto, M | 1 |
| Khatri, A | 1 |
| Cheng, L | 1 |
| Camez, A | 1 |
| Ignatenko, S | 1 |
| Pang, Y | 1 |
| Othman, AA | 1 |
| Hasselkus, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis[NCT02397382] | Phase 1 | 16 participants (Actual) | Interventional | 2015-06-18 | Completed | ||
| The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients Wit[NCT02772601] | Phase 1 | 21 participants (Actual) | Interventional | 2016-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for omeprazole and Psoriasis
| Article | Year |
|---|---|
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P | 2020 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cy | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; | 2019 |
1 other study available for omeprazole and Psoriasis
| Article | Year |
|---|---|
[Healing of chronic psoriasis vulgaris while using omeprazole].
Topics: Aged; Esophagitis, Peptic; Female; Humans; Omeprazole; Psoriasis | 1993 |